INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Directory07Corporate Insiders08Government Money09Political Influence10Institutions11Washington Network12Follow the Power13Disclosure Clock14AI Investigator15Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
01Overview02Follow the Money03Daily Brief04Live05Congress06Directory07Corporate Insiders08Government Money09Political Influence10Institutions11Washington Network12Follow the Power13Disclosure Clock14AI Investigator15Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Data sources
SEC FORM 420m ago
HOUSE PTR20m ago
SEC 13F20m ago
ROBINHOOD CHAIN20m ago
Corporate insider
SR

Sullivan Christopher Ryan

Chief Financial OfficerCIK 0001810417

EDGAR filingsOpen in network
Disclosed transactions30
Buys / sells0 / 13
Max Insider Score26
Connections1with evidence

Disclosed transactions

ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
3
SR
Sullivan Christopher RyanChief Financial Officer
AVTXAvalo Therapeutics, Inc.
Option exercise · 10b5-1 plan
M$122K
12.4K sh
Sep 16, 2026Sep 18, 2026
traded Sep 16, 2026
+2dSEC FORM 4

Evidence

Verified connections

  • Insider ofevidence
    Avalo Therapeutics, Inc.Chief Financial Officer · Mar 31, 2026
0
SR
Sullivan Christopher RyanChief Financial Officer
AVTXAvalo Therapeutics, Inc.
Option exercise · 10b5-1 plan
M
—
12.4K sh
Sep 16, 2026
Sep 18, 2026
traded Sep 16, 2026
+2d
SEC FORM 4

Evidence

9
SR
Sullivan Christopher RyanChief Financial Officer
AVTXAvalo Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$202K
12.4K sh
Sep 16, 2026Sep 18, 2026
traded Sep 16, 2026
+2dSEC FORM 4

Evidence

3
SR
Sullivan Christopher RyanChief Financial Officer
AVTXAvalo Therapeutics, Inc.
Option exercise · 10b5-1 plan
M$82K
10.2K sh
Sep 10, 2026Sep 11, 2026
traded Sep 10, 2026
+1dSEC FORM 4

Evidence

14
SR
Sullivan Christopher RyanChief Financial Officer
AVTXAvalo Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$179K
10.2K sh
Sep 10, 2026Sep 11, 2026
traded Sep 10, 2026
+1dSEC FORM 4

Evidence

0
SR
Sullivan Christopher RyanChief Financial Officer
AVTXAvalo Therapeutics, Inc.
Option exercise · 10b5-1 plan
M—
10.2K sh
Sep 10, 2026Sep 11, 2026
traded Sep 10, 2026
+1dSEC FORM 4

Evidence

0
SR
Sullivan Christopher RyanChief Financial Officer
AVTXAvalo Therapeutics, Inc.
Option exercise · 10b5-1 plan
M—
37.9K sh
Aug 17, 2026Aug 19, 2026
traded Aug 17, 2026
+2dSEC FORM 4

Evidence

0
SR
Sullivan Christopher RyanChief Financial Officer
AVTXAvalo Therapeutics, Inc.
Option exercise · 10b5-1 plan
M$28K
2,876 sh
Aug 17, 2026Aug 19, 2026
traded Aug 17, 2026
+2dSEC FORM 4

Evidence

22
SR
Sullivan Christopher RyanChief Financial Officer
AVTXAvalo Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$753K
37.9K sh
Aug 17, 2026Aug 19, 2026
traded Aug 17, 2026
+2dSEC FORM 4

Evidence

22
SR
Sullivan Christopher RyanChief Financial Officer
AVTXAvalo Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$622K
31.0K sh
Aug 18, 2026Aug 19, 2026
traded Aug 18, 2026
+1dSEC FORM 4

Evidence

0
SR
Sullivan Christopher RyanChief Financial Officer
AVTXAvalo Therapeutics, Inc.
Option exercise · 10b5-1 plan
M—
31.0K sh
Aug 18, 2026Aug 19, 2026
traded Aug 18, 2026
+1dSEC FORM 4

Evidence

15
SR
Sullivan Christopher RyanChief Financial Officer
AVTXAvalo Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$75K
3,749 sh
Aug 17, 2026Aug 19, 2026
traded Aug 17, 2026
+2dSEC FORM 4

Evidence

10
SR
Sullivan Christopher RyanChief Financial Officer
AVTXAvalo Therapeutics, Inc.
Option exercise · 10b5-1 plan
M$307K
31.0K sh
Aug 18, 2026Aug 19, 2026
traded Aug 18, 2026
+1dSEC FORM 4

Evidence

0
SR
Sullivan Christopher RyanChief Financial Officer
AVTXAvalo Therapeutics, Inc.
Option exercise · 10b5-1 plan
M—
2,876 sh
Aug 17, 2026Aug 19, 2026
traded Aug 17, 2026
+2dSEC FORM 4

Evidence

10
SR
Sullivan Christopher RyanChief Financial Officer
AVTXAvalo Therapeutics, Inc.
Option exercise · 10b5-1 plan
M$375K
37.9K sh
Aug 17, 2026Aug 19, 2026
traded Aug 17, 2026
+2dSEC FORM 4

Evidence

0
SR
Sullivan Christopher RyanChief Financial Officer
AVTXAvalo Therapeutics, Inc.
Option exercise · 10b5-1 plan
M—
18.6K sh
May 7, 2026May 11, 2026
traded May 7, 2026
+4dSEC FORM 4

Evidence

7
SR
Sullivan Christopher RyanChief Financial Officer
AVTXAvalo Therapeutics, Inc.
Option exercise · 10b5-1 plan
M$184K
18.6K sh
May 7, 2026May 11, 2026
traded May 7, 2026
+4dSEC FORM 4

Evidence

26
SR
Sullivan Christopher RyanChief Financial Officer
AVTXAvalo Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$449K
18.6K sh
May 7, 2026May 11, 2026
traded May 7, 2026
+4dSEC FORM 4

Evidence

22
SR
Sullivan Christopher RyanChief Financial Officer
AVTXAvalo Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$238K
12.3K sh
May 6, 2026May 7, 2026
traded May 6, 2026
+1dSEC FORM 4

Evidence

22
SR
Sullivan Christopher RyanChief Financial Officer
AVTXAvalo Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$197K
9,219 sh
May 6, 2026May 7, 2026
traded May 6, 2026
+1dSEC FORM 4

Evidence

26
SR
Sullivan Christopher RyanChief Financial Officer
AVTXAvalo Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$201K
8,900 sh
May 6, 2026May 7, 2026
traded May 6, 2026
+1dSEC FORM 4

Evidence

25
SR
Sullivan Christopher RyanChief Financial Officer
AVTXAvalo Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$257K
13.8K sh
May 6, 2026May 7, 2026
traded May 6, 2026
+1dSEC FORM 4

Evidence

18
SR
Sullivan Christopher RyanChief Financial Officer
AVTXAvalo Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$56K
2,700 sh
May 6, 2026May 7, 2026
traded May 6, 2026
+1dSEC FORM 4

Evidence

7
SR
Sullivan Christopher RyanChief Financial Officer
AVTXAvalo Therapeutics, Inc.
Option exercise · 10b5-1 plan
M—
47.0K sh
May 6, 2026May 7, 2026
traded May 6, 2026
+1dSEC FORM 4

Evidence

13
SR
Sullivan Christopher RyanChief Financial Officer
AVTXAvalo Therapeutics, Inc.
Option exercise · 10b5-1 plan
M$378K
47.0K sh
May 6, 2026May 7, 2026
traded May 6, 2026
+1dSEC FORM 4

Evidence

26
SR
Sullivan Christopher RyanChief Financial Officer
AVTXAvalo Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$111K
8,458 sh
Apr 29, 2026May 1, 2026
traded Apr 29, 2026
+2dSEC FORM 4

Evidence

26
SR
Sullivan Christopher RyanChief Financial Officer
AVTXAvalo Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$112K
8,457 sh
Apr 30, 2026May 1, 2026
traded Apr 30, 2026
+1dSEC FORM 4

Evidence

9
SR
Sullivan Christopher RyanChief Financial Officer
AVTXAvalo Therapeutics, Inc.
Option exercise
M—
24.2K sh
Mar 28, 2026Mar 31, 2026
traded Mar 28, 2026
+3dSEC FORM 4

Evidence

21
SR
Sullivan Christopher RyanChief Financial Officer
AVTXAvalo Therapeutics, Inc.
Option exercise
M—
24.2K sh
Mar 28, 2026Mar 31, 2026
traded Mar 28, 2026
+3dSEC FORM 4

Evidence

20
SR
Sullivan Christopher RyanChief Financial Officer
AVTXAvalo Therapeutics, Inc.
Tax withholding
F$114K
8,241 sh
Mar 28, 2026Mar 31, 2026
traded Mar 28, 2026
+3dSEC FORM 4

Evidence